Endocrinology 2012 Jan 8;153(1):69-80. Epub 2011 Nov 8.
Department of Metabolic Disorders, Amgen Inc., MS 29-1-A, One Amgen Center Drive, Thousand Oaks, California 91320, USA.
Download full-text PDF
Am J Physiol Endocrinol Metab 2009 Nov 25;297(5):E1105-14. Epub 2009 Aug 25.
Amgen Inc., MS 29-1-A, One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
Recombinant fibroblast growth factor (FGF)21 has antihyperglycemic, antihyperlipidemic, and antiobesity effects in diabetic rodent and monkey models. Previous studies were confined to measuring steady-state effects of FGF21 following subchronic or chronic administration. The present study focuses on the kinetics of biological actions of FGF21 following a single injection and on the associated physiological and cellular mechanisms underlying FGF21 actions. Read More
Proc Natl Acad Sci U S A 2009 Aug 12;106(34):14379-84. Epub 2009 Aug 12.
Amgen Inc, South San Francisco, CA 94080, USA.
FGF19 is a hormone that regulates bile acid and glucose homeostasis. Progress has been made in identifying cofactors for receptor activation. However, several functions of FGF19 have not yet been fully defined, including the actions of FGF19 on target tissues, its FGF receptor specificity, and the contributions of other cofactors, such as heparin. Read More
Int J Obes (Lond) 2014 Feb 21;38(2):183-91. Epub 2013 May 21.
Department of Diabetes NBEs and Obesity Biology, Novo Nordisk A/S, Måløv, Denmark.
Objective: Fibroblast growth factor 21 (FGF21) is a metabolic regulator of glucose and lipid metabolism. The physiological role of FGF21 is not yet fully elucidated, however, administration of FGF21 lowers blood glucose in diabetic animals. Moreover, increased levels of FGF21 are found in obese and diabetic rodents and humans compared with lean/non-diabetic controls. Read More
Diabetes 2009 Jan 7;58(1):250-9. Epub 2008 Oct 7.
Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA.
Objective: Fibroblast growth factor 21 (FGF21) has emerged as an important metabolic regulator of glucose and lipid metabolism. The aims of the current study are to evaluate the role of FGF21 in energy metabolism and to provide mechanistic insights into its glucose and lipid-lowering effects in a high-fat diet-induced obesity (DIO) model.
Research Design And Methods: DIO or normal lean mice were treated with vehicle or recombinant murine FGF21. Read More